Assembly Biosciences (ASMB) Short term Debt (2010)
Assembly Biosciences' (ASMB) quarterly Short term Debt came in at $419380.0 in Q4 2010.
Assembly Biosciences (ASMB) Short term Debt (2010) Analysis & Trends
Assembly Biosciences' Short term Debt history runs 1 years deep, the most recent figure standing at $419380.0 for Q4 2010.
- On a quarterly basis, Short term Debt changed N/A year-over-year to $419380.0 in Q4 2010; TTM through Dec 2010 was $419380.0, a N/A change from a year earlier, with the FY2010 full-year figure at $419380.0, changed N/A from the prior year.
- Short term Debt steadied at $419380.0 in Q4 2010 per ASMB's latest filing.
- Across five years, Short term Debt topped out at $419380.0 in Q4 2010 and bottomed at $419380.0 in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Assembly Biosciences | 282.74 Mn | 56.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2010 | 419,380.00 |